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ABSTRACT
Objective: To assess the comparative utility of disability progression measures in primary pro-
gressive MS (PPMS) using the PROMiSe trial data set.
Methods: Data for patients randomized to placebo (n5 316) in the PROMiSe trial were included in
this analysis. Disability was assessed using change in single (Expanded Disability Status Scale
[EDSS], timed 25-foot walk [T25FW], and 9-hole peg test [9HPT]) and composite disability meas-
ures (EDSS/T25FW, EDSS/9HPT, and EDSS/T25FW/9HPT). Cumulative and cross-sectional
unconfirmed disability progression (UDP) and confirmed disability progression (CDP; sustained
for 3 months) rates were assessed at 12 and 24 months.
Results: CDP rates defined by a $20% increase in T25FW were higher than those defined by
EDSS score at 12 and 24 months. CDP rates defined by T25FW or EDSS score were higher than
those defined by 9HPT score. The 3-part composite measure was associated with more CDP
events (41.4% and 63.9% of patients at 12 and 24 months, respectively) than the 2-part
measure (EDSS/T25FW [38.5% and 59.5%, respectively]) and any single measure. Cumulative
UDP and CDP rates were higher than cross-sectional rates.
Conclusions: The T25FW or composite measures of disability may be more sensitive to disabil-
ity progression in patients with PPMS and should be considered as the primary endpoint for
future studies of new therapies. CDP may be the preferred measure in classic randomized con-
trolled trials in which cumulative disability progression rates are evaluated; UDP may be feasi-
ble for cross-sectional studies. Neurol Neuroimmunol Neuroinflamm 2017;4:e358; doi: 10.1212/
NXI.0000000000000358
GLOSSARY
9HPT 5 9-hole peg test; CDP 5 confirmed disability progression; DMT 5 disease-modifying therapy; EDSS 5 Expanded
Disability Status Scale; GA 5 glatiramer acetate; PPMS 5 primary progressive MS; T25FW 5 timed 25-foot walk; UDP 5
unconfirmed disability progression.
Patients with primary progressive MS (PPMS) represent 10%–15% of patients with MS and
suffer the highest neurodegeneration-related disability.1–4 There are currently no approved
treatments to ameliorate disease progression in PPMS, and there are several barriers to devel-
oping therapeutics in progressive MS.2,5 Specifically, individual disability measures may lack the
sensitivity required to reveal all cases of disease progression within the defined time frame of
a clinical trial.6
The Expanded Disability Status Scale (EDSS) remains the typical outcome measure in PPMS
trials. However, it has been widely recognized as inadequate7 and is associated with several
important weaknesses.3 Other widely used measures of disability in MS include the timed 25-
foot walk (T25FW) and the 9-hole peg test (9HPT).8,9 Recent studies have suggested that
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a combined disability measure that incorpo-
rates scoring from multiple instruments—for
example, using T25FW, 9HPT, and EDSS—
may be associated with more progression
events among patients with PPMS, and thus
higher reported event rates than achieved with
any single instrument alone.9,10
The PROMiSe study represents one of the
best and largest (N 5 943) data sources on
patients with PPMS and offers a unique
opportunity to assess the value of different
functional measures of disability progression
in a clinical trial setting.11 We report here
the results of an analysis of the PROMiSe data
set undertaken to better understand the utility
of the different measures of disability progres-
sion—EDSS, T25FW, and 9HPT alone and
in combinations—and to inform the design of
future trials in PPMS.
METHODS Standard protocol approvals, registrations,
and patient consents. Participating study sites in each individ-
ual country locally ensured all necessary regulatory approvals
(e.g., institutional review boards/institutional ethics committees)
in accordance with local regulations, including local data protec-
tion regulations used in the original collection of the data for this
secondary data analysis.
Study design. The data set for this analysis was derived from the
PROMiSe study, a randomized, double-blind, placebo-controlled
clinical trial with a planned duration of 3 years.11 The design of
the PROMiSe study has been reported previously.11 In summary,
patients who took part in the PROMiSe study (N 5 943) were
randomized in a 2:1 ratio to receive glatiramer acetate (GA) 20
mg once daily (n 5 627) or identical-appearing placebo (n 5
316) by daily subcutaneous injection.11 The primary endpoint
was time to confirmed disability progression (CDP), with CDP
being defined as a change of$1 point on the EDSS sustained for
3 months in patients with a baseline EDSS score of 3.0–5.0, or
a change of $0.5 points for 3 months in those with a baseline
score of 5.5–6.5.11 Patients also completed the MS Functional
Composite (MSFC) evaluation, a 3-part test including the
T25FW and 9HPT and the Paced Auditory Serial Addition Test
(PASAT).11
Patients. Patients eligible to participate in the PROMiSe study
were aged between 30 and 65 years, with an EDSS score of
3.0–6.5, investigator-confirmed PPMS, and progressive symp-
toms including myelopathy for $6 months before screening.
Additional eligibility criteria included evidence of pyramidal
damage on neurologic examination, including a pyramidal
functional system score $2, and evidence of multilevel CNS
disease.11 Patients with any history of MS relapse, those with
lymphopenia ,3,000 cells/mL, and those who had used an
interferon-b drug, immunosuppressant, immunomodulating
agent, corticosteroid, or investigational drug within 3 months of
study initiation were not eligible to take part.11
Only data for patients randomized to placebo in the PROM-
iSe trial were included in this analysis in order to compare clinical
measures in patients with PPMS for whom the natural course of
the disease was not potentially affected by exposure to GA
treatment.
Outcome evaluations. Disability was assessed using change
in single (EDSS, T25FW, and 9HPT) and composite disability
measures. Combination endpoints were defined as progression
by EDSS or T25FW, 9HPT or T25FW, or by EDSS or
T25FW or 9HPT. The PASAT was not included in this anal-
ysis of the PROMiSe database because of the potential for
practice effects occurring from repeated administration. More-
over, the test may have limited measurement reliability, is
sometimes difficult to administer, has been used less frequently
in recent MS trials, and is not anticipated to be featured in
future trials.
As per the PROMiSe study protocol, worsening of the EDSS
was defined as a change from baseline of $1 point (for baseline
EDSS 3.0–5.0) or $0.5 points (for baseline EDSS 5.5–6.5).11
Table 1 Baseline demographic and clinical
characteristics of patients who took
part in the PROMiSe trial and were
randomized to receive placebo
Characteristic Placebo cohort (n 5 314)
Male, n (%) 163 (51.9)
White, n (%) 284 (90.5)
Mean age, y (range) 50.2 6 8.1 (23–66)
Mean time from first
symptom, y (SD)
10.7 (7.7)
Mean time from first
diagnosis, y (SD)
5.1 (5.5)
Mean EDSS score (SD) 4.9 (1.2)
Mean T25FW, s (SD) 11.2 (10.5)
Mean 9HPT,a s (SD) 30.9 (19.6)
Abbreviations: 9HPT 5 9-hole peg test; EDSS 5 Expanded
Disability Status Scale; T25FW 5 timed 25-foot walk.
aAverage across 4 trials.
Table 2 Cumulative and cross-sectional PROMiSe disease progression rates at
12 and 24 months
Progression rates
at 12 months, %
Progression rates






UDP 3M CDP UDP 3M CDP UDP 3M CDP UDP 3M CDP
EDSS alone 29.5 14.9 21.3 17.7 47.6 32.4 29.4 26.6
T25FW 20% alone 51.7 33.5 34.9 26.5 71.7 52.0 48.6 44.4
9HPT 20% alone 26.6 8.4 15.4 9.6 38.0 18.0 19.6 15.4
EDSS or T25FW 20% 58.1 38.5 42.3 32.7 77.9 59.5 53.7 49.5
T25FW 20% or
9HPT 20%
59.1 36.3 41.2 32.0 77.6 56.7 52.8 47.7
EDSS or T25FW 20%
or 9HPT 20%
63.8 41.4 47.8 37.5 82.1 63.9 57.5 52.8
Abbreviations: 3M CDP 5 3-month confirmed disability progression; 9HPT 5 9-hole peg
test; EDSS 5 Expanded Disability Status Scale; T25FW 5 timed 25-foot walk; UDP 5
unconfirmed disability progression.
For confirmed progression rates, patients who did not have the confirmation visit by the
specified time point were censored for analysis purposes.
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Worsening of the T25FW was defined as an increase of $20%
compared with baseline or as the inability to complete the
T25FW after baseline due to worsening disability (increase of
EDSS to 7.0 or higher).12 Worsening of the 9HPT was defined
as an increase of$20% compared with baseline (calculated as the
average across 4 trials: 2 in the dominant hand and 2 in the
nondominant hand) or as the inability to complete the 9HPT
after baseline due to worsening disability.12 For each measure,
rates of unconfirmed disability progression (UDP) and of 3-
month CDP were determined.
Two trial methodologies were evaluated: cumulative and
cross-sectional. The cumulative approach describes the design
of the PROMiSe trial and similar large-scale randomized clinical
trials, with outcome measurement every 3 months and disability
progression at any time point during follow-up contributing to an
overall CDP proportion. The cross-sectional approach describes
the design for simple, straightforward investigator-initiated trials
such as futility trials13 and observational studies on PPMS dis-
ability progression.10 In this case, the measurement at one follow-
up time point (e.g., 12 months) is compared with the baseline
measurement. This analysis is restricted to patients in the
PROMiSe trial receiving placebo in order to compare clinical
measures in patients with PPMS for whom the natural course
of the disease was not affected by exposure to GA treatment.
Statistical analyses. Cumulative progression rates were esti-
mated using the Kaplan-Meier methodology. For summaries by
month, 1 month was defined as 28 days. For confirmed disability
events, patients who experienced a worsening event in the mea-
sure of interest that could not be confirmed due to the patient’s
discontinuation from the trial prior to the confirmation visit were
censored at the time of the worsening. Other patients who did not
experience the progression event were censored at their last day in
the study. Cross-sectional progression rates were determined by
comparing baseline and follow-up disability measures. Patients
missing any of the 3 disability measures at baseline, the time point
of interest, or the corresponding confirmation assessment were
excluded from the analysis. The relative percentage contribution
of each disability measure to disease progression rates observed for
the combined EDSS or T25FW or 9HPT measure was derived
by determining the number of individual patients progressing on
1, 2, or all 3 outcomes measures.
RESULTS A total of 316 patients were assigned to
receive placebo in the PROMiSe study; 314 of these
patients had a postbaseline EDSS assessment, and
these patients constituted the population for the
cumulative analyses presented here. Of these, 272 pa-
tients were included in the 12-month cross-sectional
analysis, and 214 patients constitute the population
for the 24-month cross-sectional analysis. Baseline
demographic and clinical characteristics for the 314
patients who received placebo are shown in table 1.11
The baseline characteristics of the subgroup of pa-
tients assigned to receive placebo were consistent with
those of the entire PROMiSe patient population.11
Table 2 shows cumulative and cross-sectional
UDP and CDP rates at 12 and 24 months. Among
single measures, a $20% worsening in T25FW
(T25FW 20%) was associated with the highest cumu-
lative progression rates, followed by EDSS and then
a $20% worsening in 9HPT (9HPT 20%) at both
the 12- and 24-month time points. Among combined
measures, the composite of all 3 individual measures
(i.e., EDSS or T25FW 20% or 9HPT 20%) had the
highest cumulative 3-month CDP rate at both 12 and
24 months (41.4% and 63.9%, respectively). Cross-
sectional 3-month CDP rates were also highest for the
Figure 1 Comparison of cumulative and cross-sectional UDP and CDP rates for
EDSS, T25FW 20%, and 9HPT 20%
(A) EDSS rates. (B) T25FW 20% rates. (C) 9HPT 20% rates. 3M CDP 5 3-month confirmed
disability progression; 9HPT 5 9-hole peg test; EDSS 5 Expanded Disability Status Scale;
T25FW 5 timed 25-foot walk; UDP 5 unconfirmed disability progression.
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composite of all 3 scores than for any single or dual
combination of scores at both 12 and 24 months
(37.5% and 57.5%, respectively). UDP proportions
were consistently higher than CDP proportions for all
measures, with a considerably greater difference
between UDP and CDP in the cumulative incidence
of the composite of all 3 individual measures (1 year:
63.8% and 41.4%, respectively; 2 years: 82.1% and
63.9%, respectively) compared with the cross-
sectional proportions (1 year: 47.8% and 37.5%,
respectively; 2 years: 57.5% and 52.8%, respectively).
The proportion of patients with UDP and 3-
month CDP for each of the disability metrics over
the course of the study is shown in figure 1 for each
study paradigm (cumulative and cross sectional). The
T25FW 20%-alone values were closely aligned with
those from the combined EDSS-or-T25FW 20% val-
ues at all time points over the course of the study
(table 3).
The relative contribution of each of the individual
component measures—together and in different
combinations—of a 3-part composite measure
(EDSS or T25FW 20% or 9HPT 20%) is shown
in figure 2 and figure e-1 at Neurology.org/nn.
T25FW 20% had the greatest contribution to the
overall measure, followed by EDSS, and then
9HPT 20%. These figures support the notion that
CDP as defined by T25FW identifies individuals as
progressors that the other measures would not have
been identified. In other words, a greater proportion
of patients identified as progressors by T25FW were
not identified as progressors by EDSS or 9HPT, as
compared with the proportion of patients identified
as progressors by EDSS who were not identified as
progressors by T25FW or 9HPT (figure e-2).
DISCUSSION The data presented here show that
among patients with PPMS randomized to receive
placebo in the PROMiSe study, T25FW 20% at 12
and 24 months was associated with higher rates of dis-
ability progression than EDSS, and both T25FW
20% and EDSS were associated with higher disability
rates than 9HPT 20%. The 3-part combination
measure (EDSS or T25FW 20% or 9HPT 20%) was
associated with more 3-month CDP events (41.4%
and 63.9% of patients as 12 and 24 months,
respectively) than the 2-part measure (EDSS or
T25FW 20% [38.5% and 59.5%, respectively]), and
more progression events than any single measure
(EDSS, 14.9% and 32.4%, respectively; T25FW,
33.5% and 52.0%, respectively; 9HPT, 8.4% and
18.0%, respectively).
Minimal changes in the 9HPT 20% outcome
were noted over the course of the PROMiSe trial.
As such, this measure may be less suitable than EDSS
and T25FW 20% when used alone; however, 9HPT
may still have utility as part of a composite measure.
Moreover, future studies should explore thresholds
other than 20% worsening on performance measures
such as 9HPT.
A marked difference was noted between cumula-
tive and cross-sectional progression rates, which
may inform the design of PPMS trials. Cumulative
progression rates were generally higher than cross-
sectional rates, but more strikingly, there was a greater
difference between unconfirmed and CDP using the
cumulative approach. Based on our results, the nor-
mative approach to use CDP in classic randomized
controlled trials is supported. Failure to confirm dis-
ability progression may have a neurobiological basis
or may be due to measurement unreliability; it would
be preferable to exclude these from pivotal trial anal-
yses in both cases. For trials using the cross-sectional
approach, measures of UDP may still be feasible.
Such studies would be resource-sparing and less bur-
densome for participants, but would have acknowl-
edged data sparsity and methodological limitations.
The observations presented here add to a growing
body of evidence that suggests that combining spe-
cific disability measurements may be more useful in
the clinical trial setting for assessing progression in pa-
tients with PPMS than single measures.9,10,14–16 In
a retrospective database study of 181 patients with
progressive MS (primary 47% of patients and second-
ary 53% of patients), combining change in T25FW
Table 3 Disease progression rates over the course of the PROMiSe study
Measure, % patients
Month
3 6 9 12 15 18 21 24
Unconfirmed disease
progression
EDSS alone 2.2 7.7 16.0 24.2 31.8 37.2 42.5 44.9
T25FW 20% alone 2.6 20.4 40.3 48.7 53.4 60.6 66.6 70.3
9HPT 20% alone 1.3 10.6 17.0 21.9 27.6 32.6 34.9 37.0
EDSS or T25FW 20% 3.5 24.9 44.8 53.8 60.1 66.9 72.2 75.9
T25FW 20% or 9HPT 20% 3.5 26.8 46.4 54.2 61.1 67.7 73.3 77.0
EDSS or T25FW 20%
or 9HPT 20%
4.1 30.9 50.5 58.9 66.1 72.6 77.8 81.2
3-month confirmed disease
progression
EDSS alone 1.3 4.8 10.3 15.5 22.6 26.2 31.0 32.4
T25FW 20% alone 1.9 13.1 25.6 33.5 36.5 43.2 48.2 53.1
9HPT 20% alone 0.6 4.2 5.5 8.8 11.8 14.8 16.2 18.0
EDSS or T25FW 20% 2.6 15.9 30.1 39.2 43.8 50.4 56.5 60.5
T25FW 20% or 9HPT 20% 2.2 15.0 27.5 36.6 41.6 48.6 53.0 57.8
EDSS or T25FW 20%
or 9HPT 20%
2.9 17.9 32.0 42.4 48.6 55.5 60.9 64.9
Abbreviations: 9HPT 5 9-hole peg test; EDSS 5 Expanded Disability Status Scale; T25FW
5 timed 25-foot walk.
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with EDSS was significantly more predictive of
patient prognosis than EDSS alone.15 An earlier ret-
rospective database study of 161 patients with PPMS
found that when comparing single measures or 2-
instrument combinations involving EDSS, T25FW,
and 9HPT, T25FW/9HPT predicted the greatest
number of progression events after 1 year (46% of
patients progressed compared with 17%, 34%, and
20% for the individual measures, respectively), and
the combination of T25FW/EDSS predicted the
greatest number of progression events after the second
year (57% of patients progressed compared with
32%, 46%, and 24% for the individual measures,
respectively).11 An evaluation of data from the 96-
week Olympus (rituximab) trial17 in the 147 patients
with PPMS randomized to placebo found that a com-
bined measure consisting of EDSS/T25FW/9HPT
was associated with more CDP events than did any
single or dual combination measure.11 Progression
rates at 96 weeks were 61.9% and 54.8% for those
patients with an initial confirmed progression event
at 12 and 24 weeks, respectively.9 Confirmed pro-
gression rates for EDSS alone were 38.5% and
30.4%; for T25FW alone the rates were 51.0%
and 44.5%; and for the 9HPT alone the rates were
21.1% and 17.4%, respectively.9 Most recently, the
large, prospective INFORMS (fingolimod) study,
comprising patients with PPMS treated for at least
3 years, reported that a composite of EDSS, T25FW,
or 9HPT predicted more progression events (80.3%
cumulative probability of CDP) than any of the indi-
vidual components alone (EDSS 58.7%, T25FW
70.0%, and 9HPT 41.3% of patients) among those
randomized to placebo.14
Although those previous published studies offer
similar conclusions to this study regarding the relative
utility of outcome measures, they differ in several
important ways that distinguish them from our anal-
ysis of the PROMiSe data set. The retrospective data-
base study included both primary and secondary
Figure 2 Contribution of individual clinical measures evaluating patient worsening at 24 months (cross-
sectional 3-month CDP) within a 3-part combined measure (EDSS or T25FW 20% or 9HPT 20%)
(A) Cumulative UDP. (B) Cumulative 3-month CDP. (C) Cross-sectional UDP. (D) Cross-sectional 3-month CDP. 3M CDP 5
3-month confirmed disability progression; 9HPT 5 9-hole peg test; EDSS 5 Expanded Disability Status Scale; T25FW 5
timed 25-foot walk; UDP 5 unconfirmed disability progression.
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progressive patients with MS, was primarily focused
on outcomes of early vs late changes on clinical scales,
included patients who were exposed to disease-
modifying therapies (DMTs) during the course of
the study, did not set a minimum disability criterion
as per EDSS for study entry, and included less-
frequent patient assessment.15 Similarly, the earlier
study likely included patients exposed to DMTs,
while its entry criteria included an EDSS threshold
score of 2.0–6.5, representing a less-disabled patient
population than that of the PROMiSe study.10 The
same EDSS criteria applied to the Olympus study,
whereas none of these 3 studies, nor the INFORMS
study, compared confirmed with unconfirmed pro-
gression or offered a cross-sectional analysis of disease
progression data.9,14
Two other recently published studies address
similar themes and arrive at compatible conclusions
to those of this study.18,19 In one of these studies,
however, the patient population consisted entirely
of those with secondary progressive MS,18 whereas
the other had a lower EDSS inclusion threshold
(1–7), allowed inclusion of patients who had been
treated with DMTs as recently as 3 months prior to
study entry, and was intended as a validation study
of a novel disability score (CombiWISE); that scor-
ing measure, in addition to EDSS, T25FW, and
9HPT, also includes the Scripps Neurological Rat-
ing Scale.19 And, as with the previously noted stud-
ies, neither unconfirmed disease nor a cross-
sectional analysis was included in the design of
these studies.18,19 Thus, this study offers several
unique features that make it a potentially valuable
contribution to the literature, such as reflecting the
untreated natural history of PPMS by including
only patients receiving placebo, including patients
with more severe disability, comparing confirmed
and unconfirmed disease progression, and includ-
ing a cross-sectional analysis.
There is an unmet need for controlling disease
progression in patients with PPMS. For these pa-
tients, individual measures of disease progression
may limit the potential to assess the benefit of new
agents to the extent that the composite measures have
higher event rates. Based on the observations pre-
sented here and those from previous studies, future
studies of agents for the treatment of PPMS may
benefit from either using T25FW 20% as a single
outcome measure or using T25FW 20% in combina-
tion with the EDSS as a primary efficacy endpoint
rather than EDSS alone, particularly if higher event
rates over shorter exposure periods are sought. It is
largely unknown whether specific disability outcomes
would differentially detect treatment effects or
whether this would differ according to the mecha-
nism of the treatment under study.
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